(-)-Epigallocatechin Gallate

"目录号: HY-13653

Cell Cycle/DNA DamageEpigeneticsAutophagy-

(-)-Epigallocatechin Gallate 是一种天然的多酚黄酮类化合物,能够抑制telomeraseDNA methyltransferase的活性,同时阻止 EGF 受体和 HER-2 受体活化。

TelomeraseDNA MethyltransferaseAutophagy

相关产品

Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-

生物活性

Description

(-)-Epigallocatechin Gallate is an antioxidant polyphenol flavonoid that inhibitstelomeraseandDNA methyltransferase, and blocks the activation of EGF receptors and HER-2 receptors.

In Vitro

Epigallocatechin Gallate (10 μM, 40 μM, 60 μM) decreases FB-2 and WRO cell proliferation in a dose dependent manner. Epigallocatechol Gallate reduces basal3H Thymidine incorporation in a dose dependent manner reaching 78% inhibition at the concentration of 60 μM. decreases cyclin D1 and up-regulates p21WAF1/Cip1and p53 expression in FB-2 cells[1]. Epigallocatechol Gallate inhibits the proliferation of the cells studied when the concentration is increased and that the inhibition is time dependent. The expression of HES1 in the cell lines treated with 35 μg/mL epigallocatechol gallate is significantly lower than in the control group[2]. In the presence of epigallocatechin gallate aggregation is delayed, cells do not stream and development is typically stalled at the loose aggregate stage[3]. Epigallocatechol Gallate treatment is found to modify the expressions of some of the miRNAs in human hepatocellular carcinoma HepG2 cells, 13 are up-regulated and 48 are down-regulated. miR-16 is one of the miRNAs up-regulated by epigallocatechol gallate and one of its target genes is confirmed to be the anti-apoptotic protein Bcl-2. Epigallocatechol Gallate treatment induces apoptosis and down-regulates Bcl-2 in HepG2 cells[4].

In Vivo

Epigallocatechol Gallate (5 and 20 mg/kg, p.o.) inhibits the growth of tumor in the subcutaneous orthotopic transplant model[2].

Clinical Trial

NCT01687556

Seoul National University Hospital

Acne Vulgaris

July 2005

NCT01744587

National Health Research Institutes, Taiwan-Mackay Memorial Hospital-Taichung Veterans General Hospital-National Cheng-Kung University Hospital-Chang Gung Memorial Hospital-China Medical University Hospital-National Taiwan University Hospital

NPC

April 2013

Phase 2-Phase 3

NCT02580279

Shandong Cancer Hospital and Institute

Breast Neoplasms-Dermatitis-Prevention & Control-Epigallocatechin Gallate

February 2015

Phase 2

NCT02008721

Dr. Johannes Levin-German Center for Neurodegenerative Diseases (DZNE)-Deutsche Parkinson Vereinigung-Deutsche Stiftung Neurologie-ParkinsonFonds Deutschland gGmbH-Ludwig-Maximilians - University of Munich

Multiple System Atrophy

January 2014

Phase 3

NCT01846338

National Yang Ming University-Taipei City Hospital

Acne Lesion Counts

October 2012

NCT02577393

Shandong Cancer Hospital and Institute

Lung Neoplasms-Esophagitis-Prevention & Control-Epigallocatechin Gallate

June 2015

Phase 2

NCT00434499

University of Maryland

Hypertension-Obesity-Type 2 Diabetes-Insulin Resistance

February 2007

Phase 2

NCT00867555

Maastricht University Medical Center-DSM Nutritional Products, Inc.

Obesity-Type 2 Diabetes Mellitus

October 2008

NCT01394796

Parc de Salut Mar

Down Syndrome

May 2010

Phase 2

NCT02891538

The University of Texas Health Science Center at San Antonio

Colon Cancer

November 2016

NCT00981292

Northumbria University

Cognitive Function-Mood

August 2009

Phase 4

NCT01357681

Charite University, Berlin, Germany

Huntington Disease

September 2011

Phase 2

NCT01662232

Charite University, Berlin, Germany

Cardiovascular Diseases

August 2012

NCT00889434

Hadassah Medical Organization

Cystic Fibrosis

November 1, 2011

NCT01511263

IRCCS Policlinico S. Matteo

Primary Amyloidosis of Light Chain Type

January 2012

Phase 2

NCT01699711

Parc de Salut Mar

Down Syndrome (DS)

February 2012

Phase 2

NCT02015312

Florian Michel-German Federal Ministry of Education and Research-University Hospital Heidelberg

Light Chain (AL) Amyloidosis-Cardiac Involvement

April 2013

Phase 2

NCT01855971

Parc de Salut Mar

Fragile X Syndrome

June 11, 2013

NCT01018615

University of North Carolina, Chapel Hill-National Center for Complementary and Integrative Health (NCCIH)-National Institutes of Health (NIH)

Chronic Hepatitis C-Oxidative Stress

November 2009

Phase 1

NCT00799890

Charite University, Berlin, Germany-TAIYO EUROPE

Multiple Sclerosis

May 2009

Phase 2-Phase 3

NCT02731495

National Nutrition and Food Technology Institute-Tehran University of Medical Sciences

Traumatic Brain Injury

March 2015

Phase 2-Phase 3

NCT01311869

Meharry Medical College

Leiomyoma

December 2010

Phase 2

NCT01481818

Shandong Cancer Hospital and Institute

Epigallocatechin Gallate-Radio Dermatitis-Radiation Mucositis

September 2011

Phase 1-Phase 2

NCT02381145

Maastricht University Medical Center

Healthy

August 2012

NCT02147041

Taipei City Hospital-National Yang Ming University

Diabetes Mellitus-Hyperlipidemia

May 2012

Phase 2-Phase 3

NCT00611416

University of Copenhagen-Unilever R&D

Obesity

November 2005

NCT01417312

Charite University, Berlin, Germany

Multiple Sclerosis, Relapsing-Remitting

July 2011

NCT00676780

Louisiana State University Health Sciences Center Shreveport-Polyphenon Pharma

Prostate Cancer

May 2004

Phase 2

NCT02832271

Chinese University of Hong Kong

Endometriosis

December 8, 2016

Phase 2

NCT00461942

Xuanwu Hospital, Beijing-Ministry of Health, China-Michael J. Fox Foundation for Parkinson's Research

Parkinson's Disease

April 2006

Phase 2

NCT01556321

Maastricht University Medical Center

Obesity

June 2012

NCT03194620

University of California, Davis-Mars, Inc.

Healthy

August 2016

View MoreCollapse

References

[1].De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013 Apr 1.

[2].Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 2013;6:145-53.

[3].McQuade KJ, et al. The Green Tea Catechin Epigallocatechin Gallate (EGCG) Blocks Cell Motility, Chemotaxis and Development in Dictyostelium discoideum. PLoS One. 2013;8(3):e59275.

[4].Wing Pui Tsang, et al. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. The Journal of Nutritional Biochemistry. 2010, 21(2): 140-146.

你可能感兴趣的:((-)-Epigallocatechin Gallate)